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Abstract In contrast to hepatic hydrosteroid dehydrogenases
(HSDs) of the aldo-keto reductase family (AKR1C), little is
known about a stomach one. From a mouse stomach cDNA
library, we isolated two clones encoding proteins of 323 amino
acid residues. They exhibited 93.2% amino acid sequence identity
and 64^68% with any known HSDs. Recombinant proteins
expressed in Escherichia coli reduced 9,10-phenanthraquinone
with NAD(P)H as cofactor. The mRNAs were exclusively
expressed in stomach, liver and ileum. The present study
demonstrates that these proteins are new members of the HSD
subfamily and they are named AKR1C12 and AKR1C13.
Immunohistochemical analysis suggests that they are involved
in detoxification of xenobiotics in the stomach.
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1. Introduction
The aldo-keto reductases are monomeric proteins, about
320 residues in size, that share a common (K/L)8-barrel scaf-
fold [1]. These proteins catalyze reactions with a diverse range
of substrates including prostaglandins (PGs), monosacchar-
ides, steroids and xenobiotic aldehydes and ketones using
nicotinamide dinucleotide as cofactor. With the advent of
recombinant DNA techniques, the primary sequences of
enzymes belonging to the aldo-keto reductase superfamily
have been recently delineated [1]. These enzymes include alde-
hyde reductase (EC 1.1.1.2) [2], aldose reductases (EC
1.1.1.21) [2^4], bovine lung PGF synthase (PGFS) (EC
1.1.1.188) [5], chlordecone reductase (CDR) (EC 1.1.1.225)
[6], 3K-hydroxysteroid dehydrogenase (3K-HSD) (EC
1.1.1.213)/dihydrodiol dehydrogenase (DD) (EC 1.3.1.20)
[7,8], estradiol 17L-HSD (EC 1.1.1.62) [9] and 20K-HSD
(EC 1.1.1.149) [10,11]. These proteins belong to the AKR1
family according to a new nomenclature of the aldo-keto re-
ductase superfamily proposed by Jez et al. [12].
PGFS was puri¢ed to apparent homogeneity from bovine
lung and its properties have been characterized in detail [13^
15]. The enzyme exhibits a broad substrate speci¢city and
catalyzes the conversion of PGD2 to 9K,11L-PGF2 (11-keto-
reductase activity) and PGH2 to PGF2K (9,11-endoperoxide
reductase activity) as well as the reduction of various carbonyl
compounds. We previously demonstrated that expression of
PGFS-like immunoreactivity increased in mouse uterus at the
term of pregnancy accompanied with the increase in PGF2K
production [16]. In the course of the studies in the reproduc-
tive system, we found that a PGFS-immunoreactive protein(s)
was abundantly present in mouse stomach and liver. Since the
stomach is the site which is directly exposed to food, drugs
and microorganisms, it is likely that aldo-keto reductases play
an important role in this tissue. Nevertheless, little informa-
tion is available on a stomach aldo-keto reductase(s) in con-
trast to the hepatic ones which have been studied extensively
in many laboratories [1,12,17,18]. To investigate the structure
and function of the antigenetically related protein, we con-
structed a cDNA library from mouse stomach and screened
using PGFS cDNA as probe. In the present study, we report
the isolation and characterization of two novel enzymes be-
longing to the HSD subfamily of aldo-keto reductases.
2. Materials and methods
2.1. Isolation of cDNA clones and DNA sequencing
A mouse stomach cDNA library was constructed in Vgt11 by the
method of Huynh et al. [19]. The 1U106 phages of cDNA library were
hybridized with PGFS cDNA [5]. Hybridization was carried out at
37‡C in 5USSPE (1USSPC: 0.18 M NaCl, 10 mM sodium phos-
phate, pH 7.7, and 1 mM EDTA), 0.1% sodium dodecyl sulfate
(SDS), 1UDenhardt’s solution, 50% (w/v) dextran sulfate, 50% form-
amide and 0.1 mg/ml denatured salmon sperm DNA and ¢lters were
washed with 2USSC (1USSC: 0.15 M NaCl and 15 mM sodium
citrate, pH 7.0) containing 0.1% SDS at 37‡C. Eight positive phage
clones were isolated and puri¢ed. The inserts were digested with Bam-
HI and subcloned into the pBluescript SK(+) vector for DNA se-
quencing. Two plasmid clones with a high homology to PGFS
cDNA were designated as AKR1C12 and AKR1C13 and analyzed
in subsequent experiments.
2.2. Expression and puri¢cation of AKR1C12 and AKR1C13 proteins
in Escherichia coli
To express AKR1C12 and AKR1C13 proteins, the cDNAs were
subcloned into the pBluescript SK(+) plasmids in such a way that the
translation initiation signal of the L-galactosidase gene was used to
overexpress the proteins. These expression plasmids were transfected
into the host strain E. coli DH5K. Recombinant AKR1C12 and
AKR1C13 proteins were puri¢ed to apparent homogeneity from the
crude extract of transfected cells by three steps consisting of 35^75%
ammonium sulfate precipitation and Ultrogel AcA 54 (BioSepra,
France) column chromatography followed by Mono S HR5/5 column
chromatography for AKR1C12 or DEAE-cosmogel (Nacalai Tesque,
Kyoto, Japan) column chromatography for AKR1C13. The yields of
AKR1C12 and AKR1C13 were 9.8 and 66.7% and speci¢c activities
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of the puri¢ed enzymes were 7.49 and 3.36 U/mg protein using 9,10-
phenanthraquinone as substrate, respectively.
2.3. Enzyme assay
The reductase activities for 9,10-phenanthraquinone, 4-nitrobenzal-
dehyde, 4-nitroacetophenone, menadione, progesterone, cortisone,
corticosterone, esterone and D-glucose were determined spectrophoto-
metrically by the oxidation of NADPH at pH 6.5. The oxidase activ-
ities for testosterone, androsterone and estradiol were determined
spectrophotometrically by the reduction of NADP at pH 8.0.
PGD2 11-ketoreductase, PGE2 9-ketoreductase and PGH2 9,11-endo-
peroxide reductase activities were determined as described previously
[13]. One unit of enzyme activity was de¢ned as the amount that
oxidized 1 Wmol of NADPH, reduced 1 Wmol of NADP or formed
1 Wmol of PGF2 per min at 37‡C.
2.4. Miscellaneous
For immunoblotting, the membrane was immunostained with the
rabbit anti-PGFS antiserum at 1:2500 dilution, biotinylated anti-rab-
bit IgG goat serum at 1:3000 dilution and a Vectastain ABC kit
(Vector Laboratories) as described previously [15]. Protein bands
were visualized with an ECL kit (Amersham Pharmacia Biotech,
UK). For immunohistochemistry, transverse frozen sections (10 Wm
thickness) were immunostained with anti-PGFS antiserum at a 1:1000
dilution as the ¢rst antibody and immunoreactive structures were
revealed with a goat anti-rabbit IgG-Cy3 conjugate by a £uorescence
microscope (LSM-GB2000, Olympus, Tokyo, Japan). For Northern
blot analysis, total RNAs (10 Wg) isolated from various mouse tissues
were analyzed according to standard procedures [20]. The full-length
cDNA of AKR1C12 was labelled with [K-32P]dCTP by random pri-
ming and used as probe.
Fig. 1. PGFS-like immunoreactivity in mouse tissues. Crude extracts
from lung, stomach and liver were subjected to 12.5% SDS-poly-
acrylamide gel electrophoresis, transferred to a PVDF membrane
and immunostained with anti-PGFS antiserum. The arrow on the
right indicates the position of recombinant PGFS.
Fig. 2. (A) Alignment of the deduced amino acid sequences of AKR1C12 and AKR1C13. Conserved amino acids are boxed. The nucleotide se-
quences of AKR1C12 and AKR1C13 have been submitted to the DDBJ/EMBL/GenBank database and are available under accession numbers
AB027237 and AB027125, respectively. (B) Phylogenic tree of AKR1C12, AKR1C13 and HSD subfamily. Analysis of sequence homologies
among AKR1C12, AKR1C13 and entries in the Swiss Prot and PIR data banks and cluster analysis of HSDs were carried out using the GEN-
ETEX-MAC program (9.0). On the basis of the distance matrix between aligned amino acid sequences, the tree was inferred by the UPGMA
method [23].
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3. Results and discussion
3.1. Cloning and cDNA sequences of PGFS homologues
When polyclonal antibodies against PGFS were used, an
immunoreactive band was intensely detected in crude extracts
of mouse stomach and liver and weakly in lung (Fig. 1) at the
same position as that of recombinant PGFS (Mr = 36 666). A
cDNA library from mouse stomach was screened by plaque
hybridization with PGFS cDNA as probe under low strin-
gency conditions and the two PGFS homologs named
AKR1C12 and AKR1C13 were analyzed in subsequent ex-
periments.
The full-length cDNA of AKR1C12 was 1217 bp long, of
which a 19 bp 5P-£anking region and a 969 bp open reading
frame encoding a 323 amino acid polypeptide with a calcu-
lated Mr of 37 035 followed by a 229 bp 3P-untranslated re-
gion including a poly(A) tail. The cDNA insert in AKR1C13
contained 1207 bp with a 969 bp open reading frame, specify-
ing a 323 amino acid polypeptide with a Mr of 36 990 and a
226 bp 3P-untranslated region including a poly(A) tail. When
the deduced amino acid sequences of AKR1C12 and
AKR1C13 were compared, the identity between them was
93.2% without amino acid deletion/insertion (Fig. 2A). The
sequence comparison analysis revealed the signi¢cant homol-
ogy of AKR1C12 and AKR1C13 with known enzymes be-
longing to the HSD subfamily of aldo-keto reductases. The
amino acid sequence of AKR1C12 was 65, 66, 67, 67, 68 and
68% identical with those of rat corpus luteum 20K-HSD
(AKR1C8) [11], mouse liver 17L-HSD (AKR1C6) [9], human
liver 3K-HSD type 1 [8]/CDR [6,21]/DD4 (AKR1C4) [17],
PGFS (AKR1C7) [5], human liver DD2/bile acid-binding pro-
tein (AKR1C2) [17,18] and human liver DD1 (AKR1C1) [22],
respectively. The amino acid sequence of AKR1C13 was 64,
65, 65, 65, 66 and 67% identical with them in the same order.
To establish evolutionary relationships among these aldo-keto
reductases, a phylogenetic tree was constructed by the UP-
GMA method [23] (Fig. 2B). AKR1C12 and AKR1C13 pro-
teins belong to the mammalian HSD group and form a single
cluster which is separated from the other HSDs, indicating
that they constitute a closed group within the HSD subfamily.
3.2. Enzymatic activity of expressed AKR1C12 and AKR1C13
To characterize properties of AKR1C12 and AKR1C13,
these proteins were expressed in E. coli. Table 1 summarizes
the substrate speci¢city of puri¢ed recombinant AKR1C12,
AKR1C13 and PGFS. While PGFS catalyzed a reaction
with a broad spectrum of substrates including synthetic com-
pounds, PGs and testosterone, typical of aldo-keto reductases
[1], both AKR1C12 and AKR1C13 exhibited a rather selec-
tive substrate speci¢city for 9,10-phenanthraquinone. The spe-
ci¢c activities of AKR1C12 and AKR1C13 for 9,10-phenan-
thraquinone were 20- and 10-fold higher than that of PGFS.
The puri¢ed AKR1C12 reduced 4-nitrobenzaldehyde with a
speci¢c activity (0.32 U/mg) comparable to that (0.38 U/mg)
of PGFS. PGH2, progesterone, cortisone and testosterone
served as substrates for AKR1C12, but their reaction rates
were less than 0.5% of that observed with 9,10-phenanthra-
quinone. AKR1C13 almost exclusively reduced 9,10-phenan-
thraquinone among substrates examined. The Km values for
9,10-phenanthraquinone were 1.4 and 2.1 WM with AKR1C12
and AKR1C13, respectively, comparable to that (0.7 WM) of
PGFS. When NADH and NADPH were examined for their
capacity to serve as a cofactor using 9,10-phenanthraquinone
as substrate, both NADH and NADPH were similarly used as
cofactors by AKR1C12 and AKR1C13 with Km values of 20^
25 WM. When the 9,10-phenanthraquinone reductase activity
was compared between NADPH and NADH at 80 WM under
standard assay conditions, the speci¢c activity of AKR1C13
was 6-fold higher with NADPH than with NADH. In con-
trast, the speci¢c activity of AKR1C12 with NADPH was
Table 1
Comparison of substrate speci¢city among recombinant AKR1C12, AKR1C13 and PGFS
Substrate/cofactor Concentration (mM) Speci¢c activity (U/mg protein)
AKR1C12 AKR1C13 PGFSa
Synthetic
Nitrobenzaldehyde 0.5 0.32 0.03 0.38
Phenanthraquinone 0.1 7.49 3.36 0.38
Nitroacetophenone 0.5 ND ND 0.43
Menadione 0.25 ND ND 0.42
PGs
PGH2 0.08 0.012 0.0005 0.057
PGD2 1.00 0.0006 0.0002 0.13
PGE2 1.00 0.0018 ND 0.0076
Steroids
Testosterone 0.05 0.009 ND 0.004
Androsterone 0.12 ND ND ^
Progesterone 0.25 0.024 ND ^
Cortisone 0.25 0.015 ND ^
Corticosterone 0.25 ND ND ^
Esterone 0.05 ND ND ^
Estradiol 0.05 ND ND ^
D-Glucose 80 ND ND ^
Cofactor
NADPH 0.08 7.47 3.36 ^
NADH 0.08 10.2 0.55 ^
Substrate speci¢city was measured in the presence of 80 WM NADPH as cofactor and cofactor selectivity was measured with 10 WM 9,10-phe-
nanthraquinone as substrate. ND, not detected. ^, not examined.
aReported by Watanabe et al. [5].
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rather low as compared with NADH (Table 1). These results
demonstrate that both AKR1C12 and AKR1C13 are mem-
bers of aldo-keto reductases with di¡erent catalytic properties.
3.3. Distribution of AKR1C12 and AKR1C13 in mouse tissues
As shown in Fig. 3A, a single mRNA species with a size of
approximately 1.2 kb was detected with AKR1C12 cDNA as
probe. Similar results were obtained with AKR1C13 cDNA as
probe (data not shown). Expression of AKR1C12 and
AKR1C13 transcripts was restricted to stomach, ileum and
liver. None of the other tissues such as brain, lung, spleen,
kidney and the reproductive system expressed any detectable
level of the transcript.
Anti-PGFS antibodies recognized the expressed AKR1C12
intensely as did PGFS, but weakly the expressed AKR1C13.
When cryosections of mouse stomach were immunostained
with anti-PGFS antiserum, speci¢c staining was observed in
the mucosal layer of the fundic portion and pylorus of glan-
dular stomach, but not in the muscular layer (Fig. 3B, ii and
iii). Under higher magni¢cation, it was observed that the
PGFS immunoreactivity was localized to the glandular epithe-
lium composed of the surface cells arranged in ridges and
shallow pits and gastric glands (Fig. 3B, vii and viii). The
positive stains in the glandular epithelium were inhibited by
pre-absorption of the antiserum with puri¢ed AKR1C12 (Fig.
3B, v and vi). Forestomach epithelium is keratinized, strati¢ed
squamous. While staining of the keratinized layer was not
absorbed with the puri¢ed AKR1C12, the staining of the
epithelium was inhibited (Fig. 3B, i and iv), suggesting that
the epithelium was also positively stained in the forestomach.
They were not detected without anti-PGFS antiserum or by
pre-absorption of the antiserum with AKR1C13. These stud-
ies demonstrate the restriction of AKR1C12 and AKR1C13
to the epithelium of stomach.
In the present study, we cloned two cDNAs from mouse
stomach with 64^68% amino acid identity to any known en-
zymes belonging to the HSD subfamily (AKR1C) of aldo-
keto reductases. Recombinant proteins expressed in E. coli
showed a high 9,10-phenanthraquinone reductase activity
and they are designated as AKR1C12 and AKR1C13. Unlike
the seemingly ubiquitous distribution of known aldo-keto re-
ductases, Northern blot analysis of various mouse tissues
shows that AKR1C12 and AKR1C13 are con¢ned to the
digestive system. Helicobacter pylori plays a central role in
the etiology of chronic super¢cial gastritis and peptic ulcer
and seems to increase the risk for development of adenocar-
cinoma in humans [24]. Constitutive and abundant expression
of AKR1C12 and AKR1C13 in the mucosal layer of stom-
Fig. 3. (A) Northern blot of total RNAs (10 Wg of each) from various mouse tissues. The membrane was hybridized with a 32P-labelled
AKR1C12 cDNA. The positions of rRNAs are indicated on the left. (B) AKR1C12-like immunoreactivity in mouse stomach. Cryosections
(10 Wm thickness) of forestomach (i, iv) and fundus (ii, v, vii) and pylorus (iii, vi, viii) of glandular stomach were immunostained with anti-
PGFS antibody (i^iii, vii, viii) and the antibody pre-absorbed with an excess (1 mg/ml) of puri¢ed AKR1C12 (iv^vi). e and g represent surface
epithelium and gastric glands. Bars, 100 Wm (i^vi), 10 Wm (vii, viii).
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ach suggests that the enzymes serve as detoxi¢cation of poly-
cyclic aromatic hydrocarbon carcinogens. AKR1C12 and
AKR1C13 are the ¢rst HSDs highly expressed in the stomach
and these novel enzymes may have an important clinical im-
plication in organs exposed to microorganisms and xenobiot-
ics. Cloning of AKR1C12 and AKR1C13 provides the tools
required for in vivo and in vitro studies to further understand
pathophysiological roles of aldo-keto reductases in the diges-
tive system, especially stomach.
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